Daniel C Beachler
Overview
Explore the profile of Daniel C Beachler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamal-Allial A, Sponholtz T, Vojjala S, Paullin M, Papazian A, Eshete B, et al.
Pragmat Obs Res
. 2025 Feb;
16:19-25.
PMID: 39936035
Background: The National Death Index (NDI) is the gold standard for mortality data in the United States (US) but has a time lag and can be operationally intensive. This validation...
2.
Barron J, Willey V, Doherty B, Tunceli O, Waltz C, Grabner M, et al.
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(2):e70110.
PMID: 39909722
Background And Methods: The Healthcare Integrated Research Database (HIRD) is a large, comprehensive real-world data (RWD) source for health-related research. Demographic and healthcare-related characteristics of individuals are sourced from routinely...
3.
Sponholtz T, Jamal-Allial A, Vojjala S, Papazian A, Eshete B, Paullin M, et al.
Pharmacoepidemiol Drug Saf
. 2024 Aug;
33(8):e5870.
PMID: 39135502
Purpose: We investigated time trends in validation performance characteristics for six sources of death data available within the Healthcare Integrated Research Database (HIRD) over 8 years. Methods: We conducted a...
4.
Hu M, Shoaibi A, Feng Y, Lloyd P, Wong H, Smith E, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e248192.
PMID: 38656578
Importance: Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
5.
Lloyd P, Lufkin B, Moll K, Ogilvie R, McMahill-Walraven C, Beachler D, et al.
Vaccine
. 2024 Feb;
42(8):2004-2010.
PMID: 38388240
Background: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.)...
6.
Anthony M, Aroda V, Parlett L, Djebarri L, Berreghis S, Calingaert B, et al.
Diabetes Care
. 2024 Feb;
47(4):712-719.
PMID: 38363873
Objective: To assess risk of anaphylaxis among patients with type 2 diabetes mellitus who are initiating therapy with a glucagon-like peptide 1 receptor agonist (GLP-1 RA), with a focus on...
7.
Rebordosa C, Thomsen R, Tave A, Madsen M, Beachler D, Martinez D, et al.
Diabetes Obes Metab
. 2024 Jan;
26(4):1291-1304.
PMID: 38234181
Aim: To estimate risks of diabetic ketoacidosis (DKA), acute liver injury (ALI), acute kidney injury (AKI), chronic kidney disease (CKD), severe complications of urinary tract infection (UTI) and genital infection...
8.
Hoffman S, Governor S, Daniels K, Seals R, Ziyadeh N, Wang F, et al.
Menopause
. 2023 Jul;
30(8):824-830.
PMID: 37449720
Objective: To assess the risk of select safety outcomes including endometrial cancer, endometrial hyperplasia, and breast cancer among women using conjugated estrogens/bazedoxifene (CE/BZA) as compared with estrogen/progestin combination hormone therapy...
9.
Hu M, Wong H, Feng Y, Lloyd P, Smith E, Amend K, et al.
JAMA Pediatr
. 2023 May;
177(7):710-717.
PMID: 37213095
Importance: Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
10.
Lanes S, Beachler D
Pharmacoepidemiol Drug Saf
. 2023 Feb;
32(6):700-703.
PMID: 36751117
No abstract available.